Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 12/20 | 0.75 |
| ▸ | USP7 | Q93009 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | IL1B | P01584 | 3/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13243824 | 1.00 | P2RX7 (0.75) | P2RX7USP7HTTHSD17B10KDM4E | |
| Hydrochloric Acid SCHEMBL3008930 | 0.99 | P2RX7 (0.73) | P2RX7USP7HTTHSD17B10KDM4E | |
| Hydrochloric Acid SCHEMBL3008932 | 0.99 | P2RX7 (0.73) | P2RX7USP7HTTHSD17B10KDM4E | |
| SCHEMBL4140614 | 0.85 | P2RX7 (1.00) | P2RX7 | |
| SCHEMBL4144851 | 0.85 | P2RX7 (1.00) | P2RX7 | |
| SCHEMBL4140984 | 0.85 | P2RX7 (1.00) | P2RX7 | |
| SCHEMBL13243954 | 0.84 | P2RX7 (0.70) | P2RX7USP7HTTHSD17B10KDM4E | |
| SCHEMBL13243955 | 0.84 | P2RX7 (0.70) | P2RX7USP7HTTHSD17B10KDM4E | |
| SCHEMBL3005627 | 0.81 | P2RX7 (0.50) | P2RX7HTTHSD17B10KDM4ETSHR | |
| SCHEMBL13243880 | 0.81 | P2RX7 (0.51) | P2RX7KDM4EALDH1A1HPGDPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100184802-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | RENOVIS, INC. | 2010-07-22 | — | — | US | disclosed |
| US-20100184802-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | RENOVIS, INC. | 2010-07-22 | — | — | US | disclosed |
| US-20100184802-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | RENOVIS, INC. | 2010-07-22 | — | — | US | disclosed |
| WO-2007109201-A2 | BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF | RENOVIS, INC. (US) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184802-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | P2RX7, P2RX3, P2RX2 | P2RX7 1/4885USP7 4352/4885HTT 4422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.